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OBJECTIVES This study sought to investigate the influence of time, dose, and inversion time (TI) and their
interactions on myocardial infarct size measurements to establish the foundation for a
standardized protocol for multicenter trials.
BACKGROUND There is growing interest in using magnetic resonance imaging (MRI) infarct size measure-
ments as an end point in clinical trials. However, no standardized protocol exists, and there
are limited data concerning the effects of time, contrast agent dose, and TI.
METHODS First, we determined the influence of postcontrast imaging time (5 to 40 min), contrast agent
dose (0.1 vs. 0.2 mmol/kg), TI, and their interactions in an animal model (n  14). Second,
we tested whether the findings of the animal study apply to patients and are generalizable.
Therefore, we retested the diagnostic window in a multicenter study. A total of 48 patients
with first acute myocardial infarction (AMI) from three centers were imaged twice (5 and 30
min) after injection of 0.15 mmol/kg gadolinium diethylenetriamine-pentaacetate using an
adjusted TI.
RESULTS The animal study showed that the infarct size is independent of time and dose (p  0.9 and
p  0.16, respectively) using an adjusted TI. Using a fixed TI, however, infarct size is a
function of time and dose (p  0.0001 and p  0.01, respectively). The multicenter study
showed that MRI 1 (16.9  12% of left ventricle) was not statistically different from MRI 2
(16.4  12% of left ventricle, p  NS) with no difference between sites (p  NS).
CONCLUSIONS The AMI size can be measured with MRI using a contrast dose between 0.1 and 0.2 mmol/kg
and a time window of 5 to 30 min after contrast administration, provided that the TI is
adjusted. (J Am Coll Cardiol 2006;47:2027–33) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.059Cardiology Foundation
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tt has been recently shown that the magnetic resonance
maging (MRI) delayed-enhancement technique has a high
ensitivity for the detection of myocardial infarction (1–3),
nd there is growing interest in the use of MRI infarct size
easurements as an end point in clinical trials. The accuracy
f the MRI delayed-enhancement technique has been
roven in animal models (4,5), and has been tested in
atients for the assessment of acute infarction (2,4) as well
s chronic infarction (1,5). However, these studies were
ingle-center trials including only a small number of
atients.
Currently, there is no standardized protocol for assessing
yocardial infarct size. Consequently, different scanner
perators use different imaging parameters such as imaging
ime after contrast agent administration, contrast agent
ose, and time of inversion (TI) (6–8). The effects of these
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005, accepted January 2, 2006.can parameters as well as their interactions on the assess-
ent of infarct size are unknown. However, the knowledge
f the limits of these scan parameters is essential for
stablishing a standardized protocol and conducting multi-
enter studies with MRI infarct size as an end point.
herefore, we designed a multifactor study to determine the
ffects of imaging time, contrast agent dose, TI, and their
nteractions on infarct size measurements in an animal
odel with direct comparison to histology. Additionally, we
xamined whether the findings of the animal study apply to
umans by retesting the diagnostic window established in
he animal model in a second study in patients with first
cute myocardial infarction (AMI). To determine whether
ur findings were generalizable, we included consecutive
tudies from a variety of patients with AMI that were
cquired by different scanner operators at three different
RI centers.
ETHODS
ffects of time, dose, and inversion time. The effects of
ime after contrast agent application, dose of the contrast
gent, and inversion time and their interactions were as-
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Infarct Size by MRI Delayed Enhancement May 16, 2006:2027–33essed in a multifactorial animal model for which true
nfarct size could be assessed by histology.
xperimental preparation. Fourteen 20- to 30-kg mon-
rel dogs were studied. The care of all animals was in
ccordance with the Position of the American Heart Asso-
iation on Research Animal Use adopted November 15,
984. Myocardial infarction was produced by occlusion of
he left anterior descending coronary artery under sterile
onditions for 90 min followed by reperfusion. The details
f this experimental protocol have been described in detail
lsewhere (4). All animals were scanned within two days of
nfarction.
maging. The MRI scans were performed under gaseous
nesthesia (isoflurane) using a 1.5-T Siemens Sonata (Er-
angen, Germany) and a flexible surface coil. Typical in-
lane resolution was 1.2  1.2 mm, and slice thickness was
mm, no gap.
To identify regions of contractile dysfunction, electrocar-
iogram gated cine magnetic resonance images encompass-
ng the entire left ventricle (LV) were acquired during
epeated breath-holds. Short-axis views were obtained from
cm below the level of the mitral valve insertion, then every
mm throughout the whole LV. Based on the cine images,
ne short-axis slice with significant contractile dysfunction
as selected for delayed-enhancement imaging to maximize
he number of time points acquired after injection of the
ontrast agent. Delayed-enhancement imaging of the se-
ected slice was performed every 5 min for 40 min after
ntravenous injection of a contrast agent using both an
djusted TI and a fixed TI at each 5-min time point.
For the adjusted TI, inversion-recovery turboFLASH
maging was performed as previously described in detail
lsewhere (8). In brief, the TI was set by the scanner
perator to null signal from normal myocardium and elec-
rocardiogram gated images were acquired during repeated
reath holds in mid-diastole.
For fixed TI, the same slice was scanned with a fixed (not
djusted) TI. The scanner parameters were identical to
hose for the adjusted TI except that the TI was held
onstant at a predetermined value. To test the influence of
he contrast agent concentration on the accuracy of the
elayed-enhancement technique, contrast agent was given
n two different concentrations, either 0.1 or 0.2 mmol/kg
adoversetamide (Mallinckrodt) (seven animals for each
ose). The value of the predetermined fixed TI was 300 ms
Abbreviations and Acronyms
AMI  acute myocardial infarction
LV  left ventricle/ventricular
MRI  magnetic resonance imaging
SPECT  single-photon emission computed
tomographic
TI  inversion time
TTC  triphenyltetrazolium chlorideor 0.1 mmol/kg and 250 ms for 0.2 mmol/kg. gistologic examination. Animals were sacrificed, and the
earts were excised and then sectioned into 6-mm-thick
hort-axis slices starting 1 cm below the level of the mitral
alve insertion to match the cine images using a commercial
otating meat slicer. The slices matching the MR short axis
hosen for the delayed-enhancement technique were then
tained with 2% triphenyltetrazolium chloride (TTC) and
igitally photographed. The infarct extent was determined
uantitatively using the image analysis program NIH Image
National Institutes of Health, Bethesda, Maryland) as
reviously described (4).
mage analysis. Images at each 5-min time point and each
ontrast dose were randomized and analyzed blinded to
hese parameters as well as to the results of the histology.
ine images were used to define the endocardium. The
nfarct size per slice by MRI was assessed semiautomatically
y computer counting of all enhanced pixels within the
hort-axis image. Enhanced pixels were defined as pixels
ith signal intensities more than two standard deviations
bove the mean of image intensities in a remote myocardial
egion in the same image (4). Infarct size was determined as
percent of the slice by dividing the sum of enhanced pixels
y the total number of pixels within the myocardium
ultiplied by 100%. Subendocardial hypoenhanced regions
urrounded by enhancement (no reflow zone) were included
s part of the infarct territory (5,9).
ulticenter study. We retested the diagnostic window in
umans in a multicenter study setting. Therefore, we
maged patients with acute MI at three different CMR sites
t two different time points (5 and 30 min after contrast
gent injection) using a dose of 0.15 mmol/kg gadolinium
iethylenetriamine-pentaacetate and an adjusted TI. All
RI scans were performed using a 1.5-T Siemens Sonata.
atient population. Forty-eight consecutive patients with
rst documented AMI (infarct age 4 2 days, peak creatine
inase 1,433  1,285 U/l) were prospectively enrolled at
hree institutions (Robert Bosch Medical Center, Stuttgart,
ermany [site 1], Duke Cardiovascular Magnetic Reso-
ance Center, Durham, North Carolina [site 2], and the
ashville Cardiovascular MRI Institute, Nashville, Tennes-
ee [site 3]). All patients had enzymatically proven myocar-
ial necrosis (peak total creatine kinase 125 IU/l and peak
reatine kinase-MB isoenzyme 9 · 0 g/l).
Patients were excluded if they had a prior history of
yocardial infarction or contraindications to MRI. No
atient was excluded from the study for technical or image
uality reasons. The study was approved by the institutional
eview board of each enrolling institution, and all patients
ave written informed consent.
maging. Patient images were acquired in a manner iden-
ical to that of the adjusted TI animal study, i.e., using an
nversion-recovery turboFLASH pulse sequence with scan-
er settings determined as previously described (8). All
atients were scanned twice: once at 5 min and again at 30
in after administration of contrast agent (0.15 mmol/kgadoversetamide).
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May 16, 2006:2027–33 Infarct Size by MRI Delayed Enhancementmage analysis. Patient images from each site and each
ime point were randomized for blinded analysis. Infarct
ize by MRI was determined in a manner identical to that of
he animal studies, i.e., semiautomatically by computer
ounting of all enhanced pixels in the myocardium on each
f the six to eight short-axis images. Infarct size was
etermined as a percent of left ventricular mass (%LV) as
he sum of enhanced pixels from each of the six to eight
hort-axis images divided by the total number of pixels
ithin the LV myocardium multiplied by 100%. Mass in
rams was calculated assuming a specific gravity of 1.05
/cm3.
tatistical analysis. Continuous data are expressed as mean
SD. The reproducibility of MRI was analyzed using the
epeatability analysis method of Bland-Altman (10). The
ean and 95% confidence intervals were calculated as
escribed by Bland-Altman (10). One-way analysis of
ariance with repeated measures was used to determine the
ffects of time, dose, and their interactions on infarct size
easurements; p  0.05 was regarded as statistically
ignificant.
ESULTS
ffects of time, dose, and inversion time and their interac-
ions. We tested the effects of imaging time after contrast
gent administration and contrast agent dose for a large
ariety of infarct sizes, ranging from 7.9% to 46.3% of the
lice (mean 17.9%). Figure 1 shows a typical example from
he animal study arranged in chronological order. Using an
djusted TI to null normal myocardium (upper row), both
he appearance of the images and the spatial extent of
nhancement did not change over a time of 40 min.
onversely, using a fixed TI (lower row), both the general
ppearance of the images and the spatial extent of enhance-
ent changed over time.
Figure 2 compares the MR images acquired 40 min after
dministration of contrast agent of one animal using an
djusted TI (middle) and fixed TI (right) to the gold-
igure 1. Identical short-axis slices from one animal scanned at serial time p
TI) (upper row) and a fixed TI (lower row). Using an adjusted TI (upper
id not change up to 40 min after injection of contrast agent. However, using a
patial extent of enhancement changed over time.tandard histology (TTC). For adjusted TI, the enhanced
rea matches the infarct defined by histology, whereas using
fixed TI, the enhanced region acquired 40 min after
ontrast agent appears smaller than the true infarct size
efined by TTC.
The inversion times selected by the scanner operators to
ull normal myocardium were higher for the 0.1 mmol/kg
ontrast dose than for the 0.2 mmol/kg contrast agent dose
nd increased over time. For all animals, the TI was
ncreased from 265  12 ms and 237  5 ms for the scan
erformed 5 min after administration of contrast to 372 
3 ms and 331 11 ms for the scan performed 40 min after
dministration of contrast, 0.1- and 0.2-mmol/kg contrast
gent dose, respectively.
Figure 3 shows the effects of time, dose, and TI on infarct
ize measurements expressed as an MRI/TTC ratio for all
nimals. Using an adjusted TI, the infarct size is indepen-
ent of dose and time within the tested limits. Using a fixed
I, however, infarct size becomes a function of dose and
ime. Analysis of variance with repeated measures showed
hat there are no significant differences in infarct size
easurements attributable to dose (p  0.16) or time (p 
.9) or the combination effect of time and dose interaction
p  0.28) within the tested limits using an adjusted TI.
ith the use of a fixed TI, however, the measured infarct
ize was a function of time and dose (main TI effect p 
.003). The effect of the interaction between fixed TI and
ime and dose was significant, with p  0.0001 and p 
.01, respectively. The combined effect of the coefficients
or fixed TI, fixed TI  time, and fixed TI  dose (at 40
in) implies that the overall effect on infarct size would be
8.5% of the size measured by TTC for a dose of 0.1 mmol
nd 67.4% of the size measured by TTC for a dose of 0.2
mol.
ulticenter study. Table 1 summarizes the clinical char-
cteristics of the patient population. Of the 48 patients, 20
ad anterior infarction and 46 were successfully revascular-
zed before the magnetic resonance images were acquired.
using the delayed-enhancement technique with an adjusted inversion time
, both the appearance of the images and the spatial extent of enhancementoints
row)fixed TI (lower row), both the general appearance of the images and the
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Infarct Size by MRI Delayed Enhancement May 16, 2006:2027–33Figure 4 depicts a full set of short-axis views of MRI 1
nd MRI 2 acquired in three different patients. In all
atients, the presence, location, and size of the enhanced
egions were similar in both MRI scans using an adjusted
I.
On average, MRI 1 was performed 6  2 min after
dministration of contrast and the average inversion time
elected by the scanner operators was 283  23 ms,
hereas MRI 2 was performed 27  3 min after
dministration of contrast and the inversion time was 406
35 ms. Despite these differences in postcontrast
maging time, the mean infarct size for MRI 1 (16.9 
2% of LV, 26.0  21.1 g) was not statistically different
rom that of MRI 2 (16.4  12% LV, 25.9  21.3 g, p
NS for both). The range of human infarct sizes was
.1% to 51% of LV mass.
Figure 5 shows the results of Bland-Altman analysis of
he MRI data of all 48 patients expressed in %LV mass
panel A) and mass in grams (panel B). The infarct size
etermined by MRI using an adjusted TI remained constant
etween 5 and 30 min. The difference in infarct size
etween scan 1 and 2 (bias) was 0.003% LV or 0.07 g. The
igure 2. Direct comparison of the delayed-enhancement magnetic resona
n adjusted inversion time (TI) (middle) and fixed TI (right) to the
iethylenetriamine-pentaacetate; MR  magnetic resonance; TI  invers
igure 3. Effects of time (5 to 40 min), dose (0.1 mmol/kg vs. 0.2
mol/kg), and inversion time (TI) (adjusted vs. fixed) on infarct size
easurements (magnetic resonance imaging [MRI]/ triphenyltetrazolium
hloride [TTC] ratio). Using an adjusted TI, infarct size is independent of4
ose and time within the tested limits. Using a fixed TI, however, infarct
ize becomes a function of dose and time.5% confidence intervals for infarct size comparing MRI 1
nd MRI 2 were 1.6% of LV mass or 2.5 g and 2.3 g,
.e., there were no systematic differences in infarct size
etween the two MRI scans.
ISCUSSION
his is the first study evaluating appropriate imaging param-
ters to ensure the capability of MRI as a tool for conducting
ulticenter studies with infarct size as an end point. The
ain findings of this study were that acute myocardial
nfarct size can be measured independent of time and dose
ith the MRI delayed-enhancement technique using a time
indow of 5 to 30 min after administration of contrast and
contrast agent dose between 0.1 and 0.2 mmol/kg,
rovided that the TI is adjusted for image acquisition.
ffects of time, dose, and inversion time and their interac-
ions. We found that the MRI delayed-enhancement tech-
ique accurately measures acute myocardial infarct size
ndependent of time and dose within our tested limits using
n adjusted TI.
We decided to start imaging 5 min after contrast agent
njection to have sufficient time for the blood pool signal in
he LV cavity to decline and allow discrimination between
V cavity and the endocardial border of the enhanced
nfarct. From our experience, 30 min of imaging time is
ore than sufficient to perform the delayed-enhancement
echnique in animals and patients.
The results of the current study indicate that any
rotocol for assessing infarct size measurements using an
nversion-recovery MRI pulse sequence must use a
ethod of adjusting the TI. By manually adjusting the TI
o null signal from normal myocardial regions, the
ifference in image intensity between infarcted and nor-
al myocardium is maximized (2). It has been shown
hat the TI needed to null signal from normal myocar-
ium varies from subject to subject as well as with time after
ontrast injection, mainly because of pharmacokinetics (11).
einmann et al. (11) studied the pharmacokinetics of gado-
inium diethylenetriamine-pentaacetate in humans for doses of
.1 and 0.25 mmol/kg, concluding that the plasma concentra-
ion decreased by a factor of approximately 2.4 between 3 and
ages (MRI) acquired 40 min after administration of contrast agent using
-standard histology (TTC) in one animal. Gd-DPTA  gadolinium
me; TTC  triphenyltetrazolium chloride.nce im
gold0 min after administration. This decrease in contrast
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May 16, 2006:2027–33 Infarct Size by MRI Delayed Enhancementoncentration will increase myocardial T1 and thus require
corresponding increase in the TI to appropriately null
ormal myocardium.
The inversion recovery sequence is a magnitude recon-
truction. If the TI selected is too short, typically black
ands will appear in the periphery of the contrast-enhanced
egion (8) as shown in Figures 1 and 3, resulting in an
nderestimation of the infarcted area. If the TI is set too
ong, the magnetization of normal myocardium will be
bove zero and will appear gray, resulting in a reduction of
he difference in image intensities between infarcted and
ormal myocardium (8), and may reduce the accuracy of
nfarct size measurements. Accordingly, if the TI is not
ppropriately adjusted, the apparent infarct size changes
ver time and is erroneous (Figs. 1 and 3). However, we did
able 1. Patient Characteristics
Site
Number of
Patients
Mean Age
(yrs) Men/Women
ST
1 30 58  13 24/6
2 10 56  16 9/1
3 8 68  6 3/5
K creatinine kinase; LAD left anterior descending coronary artery; LCX left
yocardial infarction.igure 4. Full set of short-axis views of the two magnetic resonance imaging
iethylenetriamine-pentaacetate) in three different patients. The presence, locatot calculate regions of interest including phase cancellation
reas, and one may argue that the infarct size differences
ould be smaller.
ulticenter confirmation of the diagnostic window. This
s the first study reporting the diagnostic window of acute
yocardial infarct size measurements assessed by the MRI
elayed-enhancement technique in a multicenter setting. In
previous single-center study of chronic infarcts, Mahr-
oldt et al. (12) performed two MRI scans 10  2 min and
7  3 min after administration of contrast using an
djusted TI and a contrast dose of 0.125 mmol/kg in 20
atients and found a variance between the two scans of
2.4% of LV mass. The value reported by Mahrholdt et al.
12) is similar to the value of acute infarcts found in the
urrent study (1.6% of LV mass), although the reported
Mean Peak CK
(U/I)
Revascularized
(%)
LAD/RCA/LCX
(%)
1,376  918 100 37/33/30
1,134  652 100 40/30/30
2,112  2,694 75 63/24/13
flex coronary artery; RCA right coronary artery; STEMI ST-segment elevationEMI
(%)
80
80
75(MRI) scans (5 and 30 min after injection of 0.15 mmol/kg gadolinium
ion, and size of the enhanced regions are similar in both MRI scans.
v
m
p
a
n
I
g
e
v
s
fi
m
p
b
t
s
p
s
M
w
i
M
r
n
i
r
s
o
S
d
t
s
r
f
i
C
s
d
b
3
n
p
f
r
R
D
s
2
R
F
v
2032 Wagner et al. JACC Vol. 47, No. 10, 2006
Infarct Size by MRI Delayed Enhancement May 16, 2006:2027–33alue of the two scans found in the current study is better
ost likely because we did not remove and reposition the
atients between the two MRI scans as done by Marholdt et
l. (12). Thus, the variances reported in the current study are
ot true interstudy variances.
mplications for clinical trial design. There has been a
rowing interest in infarct size measurements as a surrogate
nd point for clinical trials. Up to this date, there has been
ery limited experience with the use of MRI for infarct
izing in randomized clinical trials. The current report is the
rst study showing the capability of MRI as a tool for
easuring infarct sizing in a multicenter setting.
Currently, 99mTc-sestamibi single-photon emission com-
uted tomography (SPECT) imaging is thought to be the
est available imaging technique for infarct size determina-
ion (13,14), and infarct size measured by SPECT has
erved as an end point in numerous studies for evaluating
otential efficacy in randomized trials and in dose-ranging
tudies (15–17). To define the role of infarct size assessed by
RI as an end point in clinical trials, one must evaluate
hether MRI offers an advantage compared with SPECT
n terms of a reduction in the sample size.
In chronic infarcts, Mahrholdt et al. (12) performed both
RI and 99mTc-sestamibi SPECT in the same patients and
eported that MRI could reduce the number of patients
eeded for a clinical trial approximately two-fold in studies
n which each patient was scanned twice. The variance
eported by Mahrholdt et al. (10) (2.4% of LV mass) was
imilar to the observed variance of the current study (1.6%
f LV mass). In general, the effect of substituting MRI for
PECT on sample size for clinical trials depends on the
esign of the study as well as on the intrinsic variation in
rue infarct size within the population of the patients under
tudy. Currently, it is unknown whether relative drop-out
ates (i.e., secondary to device implantation) as well as the
act that SPECT misses small infarcts (3) has a significant
igure 5. Results of Bland-Altman repeatability analyses of the magnet
entricular (LV) mass (A) and mass in grams (B). See text for details.mpact on sample size.onclusions. Acute myocardial infarct size can be mea-
ured independent of time and dose with the MRI
elayed-enhancement technique using a contrast dose
etween 0.1 and 0.2 mmol/kg and a time window of 5 to
0 min after administration of contrast. Magnetic reso-
ance imaging is suitable for clinical applications such as
ost-infarct risk stratification and should be considered
or research applications such as use as an end point for
andomized trials.
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